Starting August 1, 2024, Quickarrays, Inc. will be providing all products and services in place of Pantomics Inc.
SERVICES
CUSTOM TMA
ROUTINE PATHOLOGY
IHC / IMMUNOFLUORESCENCE
ISH / FISH
CONTRACTED SERVICES
PRIMARY IHC ANTIBODIES
PATHOLOGY FIELD
Hermatopathology
DETECTION SYSTEMS
ANCILLARIES
CONTROL TMA
PAC961
Pancreatic cancer tissue array, 96 cores, 48 cases from normal, various benign and malignant tumor tissues with progressive grades and TNM stages in duplicates.
Specification
Data Sheet
TNM Grading
Downloads
Price
Size
Availability
$363
1 slide
In-Stock
A | |
B | |
C | |
D | |
E | |
F | |
G | |
H | |












TNM Classification : Pancreas carcinoma
T- Primary tumor
TX - Primary tumor cannot be assessed
TO - No evidence of primary tumor
Tis - Carcinoma in situ
T1 - Tumor limited to pancreas, 2 cm or less in greatest dimension
T2 - Tumor limited to pancreas, more than 2 cm in greatest dimension
T3 - Tumor extends directly into any of the following: duodenum, bile duct, peripancreatic tissue
T4 - Tumor extends directly into any of the following: stomach, spleen, colon, adjacent large vessels
N - Regional lymph nodes
NX - Regional lymph nodes cannot be assessed
NO - No regional lymph node metastasis
N1 - Regional lymph node metastasis
N1a - metastasis in a single regional lymph node
N1b - Metastasis in multiple regional lymph nodes
M - Distant metastasis
MX - Distant metastasis cannot be assessed
MO - No distant metastasis
M1 - Distant metastasis
Human
48
96
1.5mm
4um
8
12
Paraffin
Notes:
All tissues were fixed in 10% neutral buffered formalin for 24 hours and processed using identical SOPs. Sections were picked onto Superfrost Plus or Startfrost Adhesive slides. They all have a guaranteed six month shelf-life at 4C from the date of shipment. Additional cores not listed are orientation markers and have no data. There maybe <5% core loss per slide but the core retention rate should be >90%.
Bake at 60C for 30 minutes before use. If antigen retrieving is needed, it is always a good idea to start with a protocol with weak to mild strength. Please check our TNM guide as a reference. For IHC related information on products that provide them, please contact us at info@pantomics.com for the most up-to-date information.
For research use only. Designed for IHC or ISH based protein or RNA tissue profiling in evolution and progression of pancreas cancers.

ARRAY POSITION | IMAGE | SEX | AGE | ANATOMIC SITE | PATHOLOGY | GRADE | STAGE (TNM) |
---|---|---|---|---|---|---|---|
A01 | M | 42 | Pancreas | Normal | |||
A02 | F | 59 | Pancreas | Normal | |||
A03 | M | 51 | Pancreas | Chronic inflammation | |||
A04 | M | 53 | Pancreas | Chronic inflammation | |||
A05 | F | 39 | Pancreas | Paraganglioma | |||
A06 | F | 56 | Pancreas | Serous cystadenoma | |||
A07 | M | 55 | Pancreas | Islet cell tumor | |||
A08 | M | 30 | Pancreas | Islet cell tumor | |||
A09 | M | 54 | Pancreas | Islet cell tumor | |||
A10 | M | 42 | Pancreas | Islet cell tumor | |||
A11 | M | 46 | Pancreas | Islet cell tumor | |||
A12 | F | 40 | Pancreas | Islet cell tumor | |||
B01 | M | 42 | Pancreas | Normal | |||
B02 | F | 59 | Pancreas | Normal | |||
B03 | M | 51 | Pancreas | Chronic inflammation | |||
B04 | M | 53 | Pancreas | Chronic inflammation | |||
B05 | F | 39 | Pancreas | Paraganglioma | |||
B06 | F | 56 | Pancreas | Serous cystadenoma | |||
B07 | M | 55 | Pancreas | Islet cell tumor | |||
B08 | M | 30 | Pancreas | Islet cell tumor | |||
B09 | M | 54 | Pancreas | Islet cell tumor | |||
B10 | M | 42 | Pancreas | Islet cell tumor | |||
B11 | M | 46 | Pancreas | Islet cell tumor | |||
B12 | F | 40 | Pancreas | Islet cell tumor | |||
C01 | M | 69 | Pancreas | Adenocarcinoma | I | T3N1M0 | |
C02 | F | 65 | Pancreas | Adenocarcinoma | I | T3N0M0 | |
C03 | M | 43 | Pancreas | Adenocarcinoma | I | T2N0M0 | |
C04 | F | 19 | Pancreas | Adenocarcinoma | I~II | T2N0M0 | |
C05 | M | 63 | Pancreas | Adenocarcinoma | I~II | T3N1M0 | |
C06 | M | 46 | Pancreas | Adenocarcinoma | I~II | T3N0M0 | |
C07 | M | 66 | Pancreas | Adenocarcinoma | II | T3N0M0 | |
C08 | M | 40 | Pancreas | Adenocarcinoma | II~III | T3N1M0 | |
C09 | F | 40 | Pancreas | Adenocarcinoma | II | T4N0M1 | |
C10 | F | 60 | Pancreas | Adenocarcinoma | II~III | T3N1M1 | |
C11 | M | 65 | Pancreas | Adenocarcinoma | II | T4N0M0 | |
C12 | F | 58 | Pancreas | Adenocarcinoma | II | T4N0M0 | |
D01 | M | 69 | Pancreas | Adenocarcinoma | I | T3N1M0 | |
D02 | F | 65 | Pancreas | Adenocarcinoma | I | T3N0M0 | |
D03 | M | 43 | Pancreas | Adenocarcinoma | I | T2N0M0 | |
D04 | F | 19 | Pancreas | Adenocarcinoma | I~II | T2N0M0 | |
D05 | M | 63 | Pancreas | Adenocarcinoma | I~II | T3N1M0 | |
D06 | M | 46 | Pancreas | Adenocarcinoma | I~II | T3N0M0 | |
D07 | M | 66 | Pancreas | Adenocarcinoma | II | T3N0M0 | |
D08 | M | 40 | Pancreas | Adenocarcinoma | II~III | T3N1M0 | |
D09 | F | 40 | Pancreas | Adenocarcinoma | II | T4N0M1 | |
D10 | F | 60 | Pancreas | Adenocarcinoma | II~III | T3N1M1 | |
D11 | M | 65 | Pancreas | Adenocarcinoma | II | T4N0M0 | |
D12 | F | 58 | Pancreas | Adenocarcinoma | II | T4N0M0 | |
E01 | M | 58 | Pancreas | Adenocarcinoma | II | T3N0M0 | |
E02 | F | 75 | Pancreas | Adenocarcinoma | II~III | T2N1M0 | |
E03 | M | 56 | Pancreas | Adenocarcinoma | II~III | T2N0M0 | |
E04 | M | 73 | Pancreas | Adenocarcinoma | II~III | T2N1M0 | |
E05 | M | 51 | Pancreas | Adenocarcinoma | III | T2N0M0 | |
E06 | M | 70 | Pancreas | Adenocarcinoma | III | T3N1M0 | |
E07 | M | 53 | Pancreas | Adenocarcinoma | III | T2N0M0 | |
E08 | F | 64 | Pancreas | Adenocarcinoma | III | T2N0M0 | |
E09 | F | 66 | Pancreas | Adenocarcinoma | III | T4N1M0 | |
E10 | F | 52 | Pancreas | Adenocarcinoma | III | T4N0M0 | |
E11 | F | 52 | Pancreas | Papillary carcinoma | T2N0M0 | ||
E12 | M | 58 | Pancreas | Undifferentiated carcinoma | T2N0M0 | ||
F01 | M | 58 | Pancreas | Adenocarcinoma | II | T3N0M0 | |
F02 | F | 75 | Pancreas | Adenocarcinoma | II~III | T2N1M0 | |
F03 | M | 56 | Pancreas | Adenocarcinoma | II~III | T2N0M0 | |
F04 | M | 73 | Pancreas | Adenocarcinoma | II~III | T2N1M0 | |
F05 | M | 51 | Pancreas | Adenocarcinoma | III | T2N0M0 | |
F06 | M | 70 | Pancreas | Adenocarcinoma | III | T3N1M0 | |
F07 | M | 53 | Pancreas | Adenocarcinoma | III | T2N0M0 | |
F08 | F | 64 | Pancreas | Adenocarcinoma | III | T2N0M0 | |
F09 | F | 66 | Pancreas | Adenocarcinoma | III | T4N1M0 | |
F10 | F | 52 | Pancreas | Adenocarcinoma | III | T4N0M0 | |
F11 | F | 52 | Pancreas | Papillary carcinoma | T2N0M0 | ||
F12 | M | 58 | Pancreas | Undifferentiated carcinoma | T2N0M0 | ||
G01 | M | 63 | Pancreas | Mucinous cystadenocarcinoma | T2N0M0 | ||
G02 | M | 56 | Pancreas | Mucinous cystadenocarcinoma | T2N0M0 | ||
G03 | M | 39 | Pancreas | Serous cystadenocarcinoma | T4N0M0 | ||
G04 | M | 66 | Pancreas | Adenosquamous carcinoma | T2N0M0 | ||
G05 | M | 30 | Pancreas | Mixed acinar-endocrine carcinoma | T2N0M0 | ||
G06 | F | 36 | Pancreas | Mixed acinar-endocrine carcinoma | T2N0M0 | ||
G07 | F | 20 | Pancreas | Neuroendocrine carcinoma | T2N0M0 | ||
G08 | F | 45 | Pancreas | Neuroendocrine carcinoma | T2N0M0 | ||
G09 | F | 60 | Pancreas | Neuroendocrine carcinoma | T3N1M0 | ||
G10 | F | 40 | Pancreas | Neuroendocrine carcinoma | T2N0M0 | ||
G11 | M | 59 | Pancreas | Neuroendocrine carcinoma | T2N1M0 | ||
G12 | F | 46 | Pancreas | Neuroendocrine carcinoma | T2N0M0 | ||
H01 | M | 63 | Pancreas | Mucinous cystadenocarcinoma | T2N0M0 | ||
H02 | M | 56 | Pancreas | Mucinous cystadenocarcinoma | T2N0M0 | ||
H03 | M | 39 | Pancreas | Serous cystadenocarcinoma | T4N0M0 | ||
H04 | M | 66 | Pancreas | Adenosquamous carcinoma | T2N0M0 | ||
H05 | M | 30 | Pancreas | Mixed acinar-endocrine carcinoma | T2N0M0 | ||
H06 | F | 36 | Pancreas | Mixed acinar-endocrine carcinoma | T2N0M0 | ||
H07 | F | 20 | Pancreas | Neuroendocrine carcinoma | T2N0M0 | ||
H08 | F | 45 | Pancreas | Neuroendocrine carcinoma | T2N0M0 | ||
H09 | F | 60 | Pancreas | Neuroendocrine carcinoma | T3N1M0 | ||
H10 | F | 40 | Pancreas | Neuroendocrine carcinoma | T2N0M0 | ||
H11 | M | 59 | Pancreas | Neuroendocrine carcinoma | T2N1M0 | ||
H12 | F | 46 | Pancreas | Neuroendocrine carcinoma | T2N0M0 | ||
null |